Bioavailability of gliclazide from some formulation tablets

International Journal of Pharmaceutics

Volumn 172, Issue 1-2, 1998, Pages 71-77

  Glowka F K ^a   Hermann, T W ^a   Zabel, M ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Bioavailabilty; Gliclazide; Humans; Hypoglycemic effect; Release in vitro; Serum; Tablets; Volunteers

Indexed keywords

DIABEZID; DIABREZIDE; DIAPREL; GLICLAZIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; VOLUNTEER;

EID: 0032531670     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(98)00167-7     Document Type: Article

References (12)

1. Cambell D.B., Lavielle R., Nathan C. The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res. 14(Suppl.):1991;S21-36.
2. Diaprel®, gliclazide, Questions and Answers, Les Laboratoires Servier, Gidy 45400 Fleury-les-Aubrais, France, pp. 1-25.
3. Główka F.K., Hermann T.W. Use of solid phase extraction in quantitative determination of gliclazide in human serum by HPLC. Chem. Anal. (Warsaw). 42:1997;215-219.
4. Harrower A.D.B. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J. Diabetes Complications. 8:1994;201-203.
5. Ishibashi F., Takashina S. The effect of timing on gliclazide absorption and action. J. Med. Sci. (Hiroshima). 39:1990;7-9.
6. Jennings A.M., Wilson R.M., Ward J.D. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care. 12:1989;203-208.
7. Kobayashi K., Kimura M., Sakoguchi T., Hase A., Matsuoka A., Kaneko S. Pharmacokinetics of gliclazide in healthy and diabetic subjects. J. Pharm. Sci. 73:1984;1684-1687.
8. Reynolds, J., Martindale: The Extra Pharmacopoeia XXX, The Pharmaceutical Press, London, 1993, p. 279.
9. Moffat, A.C. (Ed.), Clarke's Isolation and Identification of Drugs in Pharmaceuticals, Body Fluids and Post-Mortem Material, The Pharmaceutical Press, London, 1986, p. 640.
10. Palmer K.J., Brogden R.N. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in NIDDM. Drugs. 46:1993;92-125.
11. Tessier D., Dawson K., Tetrault J.P., Bravo G., Meneilly G.S. Glibenclamide vs. gliclazide in type 2 diabetes of the elderly. Diabetic Med. 11:1994;974-980.
12. Wieniawski, W., Polish Pharmacopoeia V, vol.2, The Polish Pharmaceutical Society, Warsaw, pp. 61-65.